Filing Details
- Accession Number:
- 0001209191-20-021490
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2020-03-27 18:27:15
- Reporting Period:
- 2020-03-26
- Accepted Time:
- 2020-03-27 18:27:15
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1595893 | Turning Point Therapeutics Inc. | TPTX | Pharmaceutical Preparations (2834) | 463826166 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1772259 | Jean Jingrong Cui | C/O Turning Point Therapeutics, Inc. 10628 Science Center Drive, Ste. 200 San Diego CA 92121 | Yes | No | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Disposition | 2020-03-26 | 6,600 | $45.37 | 786,991 | No | 4 | S | Indirect | By spouse |
Common Stock | Disposition | 2020-03-26 | 3,052 | $46.55 | 783,939 | No | 4 | S | Indirect | By spouse |
Common Stock | Disposition | 2020-03-26 | 1,648 | $47.48 | 782,291 | No | 4 | S | Indirect | By spouse |
Common Stock | Disposition | 2020-03-26 | 200 | $48.06 | 782,091 | No | 4 | S | Indirect | By spouse |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | S | Indirect | By spouse |
No | 4 | S | Indirect | By spouse |
No | 4 | S | Indirect | By spouse |
No | 4 | S | Indirect | By spouse |
Reported Non-Derivative Holdings
Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
---|---|---|---|
Common Stock | 1,001,298 | Direct | |
Common Stock | 300,000 | Indirect | By The Jean Cui 2020 GRAT |
Footnotes
- Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted by Yishan (Peter) Li.
- The weighted average sale price for the transaction reported was $45.37, and the range of prices were between $45.02 and $46.01. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
- The weighted average sale price for the transaction reported was $46.55, and the range of prices were between $46.04 and $47.01. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
- The weighted average sale price for the transaction reported was $47.48, and the range of prices were between $47.06 and $47.97. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.